User menu

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.

Bibliographic reference Combe, Bernard ; Dasgupta, Bhaskar ; Louw, Ingrid ; Pal, Sarvajeet ; Wollenhaupt, Jürgen ; et. al. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.. In: Annals of the Rheumatic Diseases, Vol. 73, no. 8, p. 1477-1486 (2013)
Permanent URL http://hdl.handle.net/2078.1/156554
  1. Galloway J. B., Hyrich K. L., Mercer L. K., Dixon W. G., Fu B., Ustianowski A. P., Watson K. D., Lunt M., Symmons D. P. M., , , Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly, 10.1093/rheumatology/keq242
  2. Lopez-Olivo Maria A., Tayar Jean H., Martinez-Lopez Juan A., Pollono Eduardo N., Cueto Jose Polo, Gonzales-Crespo M. Rosa, Fulton Stephanie, Suarez-Almazor Maria E., Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy : A Meta-analysis, 10.1001/2012.jama.10857
  3. SINGH J. A., NOORBALOOCHI S., SINGH G., Golimumab for Rheumatoid Arthritis: A Systematic Review, 10.3899/jrheum.091466
  4. Weinblatt M. E., Fleischmann R., Huizinga T. W. J., Emery P., Pope J., Massarotti E. M., van Vollenhoven R. F., Wollenhaupt J., Bingham C. O., Duncan B., Goel N., Davies O. R., Dougados M., Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study, 10.1093/rheumatology/kes150
  5. Burmester G. R, Mariette X., Montecucco C., Monteagudo-Saez I., Malaise M., Tzioufas A. G, Bijlsma J. W J, Unnebrink K., Kary S., Kupper H., , Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial, 10.1136/ard.2006.066761
  6. de Punder Yvonne M. R., Fransen Jaap, Kievit Wietske, Houtman Pieternella M., Visser Henk, van de Laar Mart A. F. J., van Riel Piet L. C. M., The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry, 10.1093/rheumatology/kes078
  7. Mancarella, J Rheumatol, 34, 1670 (2007)
  8. Hyrich K. L., Watson K. D., Lunt M., Symmons D. P. M., , Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008, 10.1093/rheumatology/keq209
  9. Greenberg Jeffrey D, Reed George, Decktor Dennis, Harrold Leslie, Furst Daniel, Gibofsky Allan, DeHoratius Ralph, Kishimoto Mitsumasa, Kremer Joel M, A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry, 10.1136/annrheumdis-2011-150573
  10. Aletaha Daniel, Ward Michael M., Machold Klaus P., Nell Valerie P. K., Stamm Tanja, Smolen Josef S., Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states, 10.1002/art.21235
  11. Zhuang Yanli, Xu Zhenhua, Frederick Bart, de Vries Dick E., Ford Joyce A., Keen Monica, Doyle Mittie K., Petty Kevin J., Davis Hugh M., Zhou Honghui, Golimumab Pharmacokinetics After Repeated Subcutaneous and Intravenous Administrations in Patients with Rheumatoid Arthritis and the Effect of Concomitant Methotrexate: An Open-Label, Randomized Study, 10.1016/j.clinthera.2011.11.015
  12. Xu Zhenhua, Wang Qingmin, Zhuang Yanli, Frederick Bart, Yan Hong, Bouman-Thio Esther, Marini Joseph C., Keen Monica, Snead David, Davis Hugh M., Zhou Honghui, Subcutaneous Bioavailability of Golimumab at 3 Different Injection Sites in Healthy Subjects, 10.1177/0091270009340782
  13. Zhou Honghui, Jang Haishan, Fleischmann Roy M., Bouman-Thio Esther, Xu Zhenhua, Marini Joseph C., Pendley Charles, Jiao Qun, Shankar Gopi, Marciniak Stanley J., Cohen Stanley B., Rahman Mahboob U., Baker Daniel, Mascelli Mary Ann, Davis Hugh M., Everitt Daniel E., Pharmacokinetics and Safety of Golimumab, a Fully Human Anti-TNF-α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis, 10.1177/0091270006298188
  14. Grigor Catriona, Capell Hilary, Stirling Anne, McMahon Alex D, Lock Peter, Vallance Ramsay, Porter Duncan, Kincaid Wilma, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial, 10.1016/s0140-6736(04)16676-2
  15. Emery Paul, Fleischmann Roy, van der Heijde Désirée, Keystone Edward C., Genovese Mark C., Conaghan Philip G., Hsia Elizabeth C., Xu Weichun, Baratelle Anna, Beutler Anna, Rahman Mahboob U., The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy, 10.1002/art.30263
  16. Weinblatt, Ann Rheum Dis
  17. TAYLOR P. C., RITCHLIN C., MENDELSOHN A., BAKER D., KIM L., XU Z., MACK M., KREMER J., Maintenance of Efficacy and Safety with Subcutaneous Golimumab Among Patients with Active Rheumatoid Arthritis Who Previously Received Intravenous Golimumab, 10.3899/jrheum.110570
  18. Tanaka Yoshiya, Harigai Masayoshi, Takeuchi Tsutomu, Yamanaka Hisashi, Ishiguro Naoki, Yamamoto Kazuhiko, Miyasaka Nobuyuki, Koike Takao, Kanazawa Minoru, Oba Takuya, Yoshinari Toru, Baker Daniel, Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study, 10.1136/ard.2011.200317
  19. Kremer Joel, Ritchlin Christopher, Mendelsohn Alan, Baker Daniel, Kim Lilianne, Xu Zhenhua, Han John, Taylor Peter, Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study, 10.1002/art.27348
  20. Smolen Josef S, Kay Jonathan, Doyle Mittie K, Landewé Robert, Matteson Eric L, Wollenhaupt Jürgen, Gaylis Norman, Murphy Frederick T, Neal Jeffrey S, Zhou Yiying, Visvanathan Sudha, Hsia Elizabeth C, Rahman Mahboob U, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial, 10.1016/s0140-6736(09)60506-7
  21. Keystone E C, Genovese M C, Klareskog L, Hsia E C, Hall S T, Miranda P C, Pazdur J, Bae S-C, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman M U, Golimumab, a human antibody to tumour necrosis factor   given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study, 10.1136/ard.2008.099010
  22. Emery Paul, Fleischmann Roy M., Moreland Larry W., Hsia Elizabeth C., Strusberg Ingrid, Durez Patrick, Nash Peter, Amante Eric Jason B., Churchill Melvin, Park Won, Pons-Estel Bernardo Antonio, Doyle Mittie K., Visvanathan Sudha, Xu Weichun, Rahman Mahboob U., Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis, 10.1002/art.24638
  23. Smolen J. S., Aletaha D., Bijlsma J. W. J., Breedveld F. C., Boumpas D., Burmester G., Combe B., Cutolo M., de Wit M., Dougados M., Emery P., Gibofsky A., Gomez-Reino J. J., Haraoui B., Kalden J., Keystone E. C., Kvien T. K., McInnes I., Martin-Mola E., Montecucco C., Schoels M., van der Heijde D., , Treating rheumatoid arthritis to target: recommendations of an international task force, 10.1136/ard.2009.123919
  24. Combe B, Landewe R, Lukas C, Bolosiu H D, Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes J M W, Klareskog L, Machold K, Martin-Mola E, Nielsen H, Silman A, Smolen J, Yazici H, EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT), 10.1136/ard.2005.044354
  25. Smolen J. S., Landewe R., Breedveld F. C., Dougados M., Emery P., Gaujoux-Viala C., Gorter S., Knevel R., Nam J., Schoels M., Aletaha D., Buch M., Gossec L., Huizinga T., Bijlsma J. W. J. W., Burmester G., Combe B., Cutolo M., Gabay C., Gomez-Reino J., Kouloumas M., Kvien T. K., Martin-Mola E., McInnes I., Pavelka K., van Riel P., Scholte M., Scott D. L., Sokka T., Valesini G., van Vollenhoven R., Winthrop K. L., Wong J., Zink A., van der Heijde D., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs, 10.1136/ard.2009.126532
  26. Singh Jasvinder A., Furst Daniel E., Bharat Aseem, Curtis Jeffrey R., Kavanaugh Arthur F., Kremer Joel M., Moreland Larry W., O'Dell James, Winthrop Kevin L., Beukelman Timothy, Bridges S. Louis, Chatham W. Winn, Paulus Harold E., Suarez-almazor Maria, Bombardier Claire, Dougados Maxime, Khanna Dinesh, King Charles M., Leong Amye L., Matteson Eric L., Schousboe John T., Moynihan Eileen, Kolba Karen S., Jain Archana, Volkmann Elizabeth R., Agrawal Harsh, Bae Sangmee, Mudano Amy S., Patkar Nivedita M., Saag Kenneth G., 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis : 2012 ACR RA Treatment Recommendations, 10.1002/acr.21641